For MOTS-c, research protocols discussed in investigational contexts vary widely, but often involve subcutaneous administration of 5-15 mg, 2-3 times weekly
Ozempic, a brand name for the drug semaglutide, was originally developed to manage type 2 diabetes by improving blood sugar control
Image: Tatsiana Volkava/Getty Images About the Author Joyce Hendley, Staff Writer About the Reviewer Robert H
Quick Answer: Tirzepatide burning at injection site is a recognized adverse reaction occurring in approximately 3.4% of patients, typically caused by the medication's formulation pH, tissue distension, or individual sensitivity, and usually resolves spontaneously within minutes to hours
To learn how to inject your medication subcutaneously, please watch this video